Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display

1125 - Randomized phase II trial of S-1 plus cisplatin or docetaxel plus cisplatin with concurrent thoracic radiotherapy for inoperable stage III non-small cell lung cancer (TORG1018): An interim report


08 Oct 2016


Poster Display


Kazuhiko Yamada


Annals of Oncology (2016) 27 (6): 411-415. 10.1093/annonc/mdw382


K. Yamada1, T. Shimokawa2, H. Okamoto2, H. Tanaka2, K. Kubota2, K. Kishi2, H. Saitho2, Y. Takiguchi2, Y. Hosomi2, T. Kato2, D. Harada2, N. Masuda2, T. Kasai2, Y. Nakamura2, K. Minato2, T. Kaburagi2, K. Naoki2, K. Hikino2, T. Yamanaka2, K. Watanabe2

Author affiliations

  • 1 Division Of Respirology, Neurology, And Rheumatology, Department Of Internal Medicine, Kurume University, 830-0011 - Kurume/JP
  • 2 Torg1018 Study Group, Thoracic Oncology Research Group, Yokohama/JP


Abstract 1125


Concurrent chemoradiotherapy (CCRT) is the current standard treatment for inoperable stage III non-small cell lung cancer (NSCLC), and a clearly superior regimen has not yet been identified. This study was conducted to evaluate cisplatin with S-1 (SP) or docetaxel (DP) with concurrent thoracic radiotherapy in patients with inoperable stage III NSCLC.


In this open-label, non-comparative phase II trial, patients with inoperable stage IIIA/B NSCLC were randomized (1:1) to SP (S-1 40 mg/m2 twice a day on days 1-14 and 29-42, and cisplatin 60 mg/m2 on days 1 and 29) or DP (docetaxel 50 mg/m2 and cisplatin 60 mg/m2 on days 1 and 29). In both arms, concurrent radiotherapy was started on day 1 (total 60 Gy in 30 fractions). After CCRT, patients in each group received two additional cycles of consolidation chemotherapy with the same regimen as that for the CCRT part. The primary endpoint was the 2-year overall survival (OS) rate,, and secondary endpoints were OS, progression-free survival (PFS), toxicity profile, dose intensity and objective response rate (ORR).


Between May 2011 and August 2014, 110 patients from 19 institutions were enrolled. Finally, 106 patients (56 in each arm) were evaluable for efficacy and safety. The patient characteristics were: male/female, 83/23; median age, 65 (range 42-74) yr; ECOG performance status 0/1, 59/47; IIIA/IIIB, 59/47. After a median follow-up of 23.1 months, ORR and median PFS were 71.7% (95%CI: 57.7-83.2) and 11.5 months (95%: 9.00-14.1) in the SP arm, and 67.9% (95%CI: 53.7-80.1) and 17.2 months (95%: 9.62-24.0) in the DP arm, respectively. Grade 3-4 leukopenia (34.0%/62.3%) and neutropenia (28.3%/56.6%) were significantly higher in the DP arm than in the SP arm. Incidences of non-hematological toxicity including febrile neutropenia, anorexia, nausea, diarrhea, radiation pneumonitis and esophagitis tended to be high in the DP arm. No treatment-related death occurred.


At this preliminary stage, it appears that although the DP arm may have more toxic effects than the SP arm, it has a favorable PFS. The OS data will be available soon.

Clinical trial identification


Legal entity responsible for the study

Thoracic Oncology Research Group


Thoracic Oncology Research Group


T. Shimokawa, H. Okamoto: I have received research funding from Takeda, MSD, Ono, Astrazeneca, Merck, Chugai, Taiho, Bristol, Eli Lilly and Parexel. K. Kubota: Honoraria: Taiho, Chugai, Eli-Lilly.

Y. Takiguchi: Grants and lecture fees from Chugai, Bristol-Myers Squibb, Kyowa Hakko Kirin, Merck Serono, Boehringer Ingelheim Japan, Ono, Taiho, grants from Eli Lilly Japan, Mochida, lecture fees from AstraZeneca Japan, outside the submitted work. Y. Hosomi: Speaker Fees as honoraria from Chugai, Eli Lilly Japan, AstraZeneca, Taiho and Ono, outside the submitted work. T. Kato: Taiho pharmaceuticals: Lecture fee and research grant. T. Yamanaka: Honoraria: Taiho, Chugai, Takeda. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings